Scott Byrd

Scott is an Entrepreneur-in-Residence on the Frazier Life Sciences team and has over 25 years of experience in the pharmaceutical industry.

Scott joined the Frazier Life Sciences team as an Entrepreneur-in-Residence in May 2020. He currently serves as the Chairman of the Board of Acacia Pharma Group plc. Previously, he was Chief Executive Officer at Outpost Medicine, a Frazier portfolio company.

Prior to Outpost, Scott was President and Chief Operating Officer of Acacia Pharma, Inc. From 2009 until its acquisition by Mallinckrodt Pharmaceuticals in 2014, he was Senior Vice President and Chief Commercial Officer of Cadence Pharmaceuticals. At Cadence, Scott built the company’s commercial and supply-chain infrastructure and led the launch of OFIRMEV, a market-leading non-opioid injectable analgesic. Earlier in his career, Scott served in a variety of roles of increasing responsibility at Eli Lilly and Company, including sales, marketing, development, manufacturing, and strategic planning.

Scott holds a B.S. in mechanical engineering from Bradley University and an M.B.A. from Harvard Business School.